Similar articles for PMID: 25550543

Year	Number of Results
1999	1
2000	1
2001	1
2002	2
2003	2
2005	4
2006	3
2007	7
2008	3
2009	5
2010	6
2011	6
2012	6
2013	9
2014	12
2015	30
2016	30
2017	18
2018	23
2019	23
2020	14
2021	17
2022	8
2023	1

1

Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.

Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T, Oga A, Ito H, Yoshino S, Hazama S, Tamada K, Yagita H, Oka M. Shindo Y, et al. Anticancer Res. 2015 Jan;35(1):129-36. Anticancer Res. 2015. PMID: 25550543

2

Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.

Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ. Lee H, et al. J Surg Res. 2011 Jul;169(1):e43-50. doi: 10.1016/j.jss.2011.03.067. Epub 2011 Apr 21. J Surg Res. 2011. PMID: 21571303

3

Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.

Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, Imawari M. Omori R, et al. Cancer Gene Ther. 2012 Sep;19(9):637-43. doi: 10.1038/cgt.2012.42. Epub 2012 Jul 13. Cancer Gene Ther. 2012. PMID: 22790963

4

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Allard B, Pommey S, Smyth MJ, Stagg J. Allard B, et al. Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983257

5

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S. Guo Z, et al. J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y. J Transl Med. 2015. PMID: 26219551 Free PMC article.

6

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

Azpilikueta A, Agorreta J, Labiano S, Pérez-Gracia JL, Sánchez-Paulete AR, Aznar MA, Ajona D, Gil-Bazo I, Larrayoz M, Teijeira A, Rodriguez-Ruiz ME, Pio R, Montuenga LM, Melero I. Azpilikueta A, et al. J Thorac Oncol. 2016 Apr;11(4):524-36. doi: 10.1016/j.jtho.2016.01.013. Epub 2016 Feb 1. J Thorac Oncol. 2016. PMID: 26845193 Free article.

7

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Li B, et al. Clin Immunol. 2007 Oct;125(1):76-87. doi: 10.1016/j.clim.2007.07.005. Epub 2007 Aug 13. Clin Immunol. 2007. PMID: 17706463

8

Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H. Mitsui J, et al. Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243. Epub 2010 May 11. Clin Cancer Res. 2010. PMID: 20460483

9

Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.

Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Kim JA, et al. Cancer Res. 2001 Mar 1;61(5):2031-7. Cancer Res. 2001. PMID: 11280763

10

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

Gauttier V, Judor JP, Le Guen V, Cany J, Ferry N, Conchon S. Gauttier V, et al. Int J Cancer. 2014 Dec 15;135(12):2857-67. doi: 10.1002/ijc.28943. Epub 2014 May 23. Int J Cancer. 2014. PMID: 24789574 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed